Novan, Inc. (NASDAQ:NOVN) Q4 2022 Earnings Call Transcript

Page 8 of 8

John Gay: Yes, just to your point as it relates to the cost Oren, obviously anything that we do from preparing for launch in addition to what Paula just mentioned as it relates to product preparedness, that is going to be rolled up into R&D expenses, to my earlier point on an earlier question, which is why we’re going to see effectively the same level of R&D spend next year that we did this year. But to Paula’s point, that amount of cost will be able to get us to a point of the initial launch.

Oren Livnat: Thanks for the clarity.

John Gay: Certainly.

Operator: Thank you. This concludes the question and answer session. I would like to turn the floor to Paula Brown Stafford for any closing comments.

Paula Brown Stafford: Okay, thank you Operator, and thank you all for joining, for really good questions this morning in an extended call. Novan is in a solid position to succeed with this potential launch. We’re on track for our January 5 PDUFA date, so we remain focused and excited for our future. We appreciate you being on the journey with us, so thank you. Have a great day.

Operator: Thank you. The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect your lines.

Follow Noven Pharmaceuticals Inc (VTX:NOVN)

Page 8 of 8